L’administration d’une seule perfusion de CARVYKTI®▼ (ciltacabtagène autoleucel) a permis d’obtenir une rémission sans traitement pendant cinq ans chez 50 pour cent des patients atteints d’un myélome multiple en rechute/réfractaire traité à un stade précoce du parcours thérapeutique
BEERSE, BELGIQUE, 28 sept. 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson, leader mondial dans le domaine du myélome multiple, a annoncé aujourd’hui de nouvelles données de suivi à long terme issues du sous-groupe initial de la cohorte A de l’étude de la Phase 2 CARTITUDE-2 (N = 20), montrant que 50 pour cent des patients …
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Jenny McCarthy Begins Therapeutic Plasma Exchange Journey to Address Mold Toxicity and Environmental Toxins
- Dairy Council of California Launches New Explore Nutrition Educational Product to Help Upper Elementary Students Discover Food, Health and Agriculture
- Internet Society Launches Global Online Trust and Safety Hub as Part of Its Safer Internet Initiative
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →